Biocomposites, which use fungal mycelium as a binder for the particles, are an emerging option in biodegradable and naturally sourced materials. This study aimed to make Pleurotus sajor-caju ...

4D printing of tubular biocomposites reveals moisture-sensitive actuators, offering insights into programmable materials for environmental responsiveness.

Novo Holdings partners with TA to reinvest in biocomposites, driving innovation and sustainable growth in the pharmaceutical industry.

Novo Holdings’ investment alongside Biocomposites’ existing shareholder, TA Associates, will help the company scale its pipeline.

As part of the transaction TA, Biocomposites' majority shareholder since 2017, will reinvest in the Company alongside new investor Novo Holdings and Biocomposites' management.

As part of the transaction TA, Biocomposites' majority shareholder since 2017, will reinvest in the Company alongside new investor Novo Holdings and Biocomposites' management.

Since partnering with TA in 2017, Biocomposites has achieved significant growth – including a threefold increase in revenues, successful geographic expansion, and continued product diversification.

"TA has been a fantastic long-term partner to us, and we are excited for the future alongside them and Novo Holdings," said Michael Harris, Biocomposites' CEO.